NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 11 January 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Raju Reddy (Vice-chair) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Items 5.1.1 to 5.2.2
5. Paul Caulfield Present for all items
6. Professor Sofia Dias Present for all items
7. Andrew Fox Present for all items
8. Christopher Herring Items 1.1 to 4.1.3
9. Dr Andrew Hitchings Present for all items
10. Dr Robert Hodgson Present for all items
11. Dr Bernard Khoo Present for all items
12. Dr Ivan Koychev Present for all items
13. Dr Guy Makin Present for all items
14. Dr Philip Mallender Present for all items
15. Professor David Meads Present for all items
16. Dr Nathan Moore Present for all items
17. Dr Paula Parvulescu Present for all items
18. Dr Rebecca Payne Present for all items
19. Carole Pitkeathley Present for all items
20. Dr Ben Searle Present for all items
21. Will Sullivan Items 1.1 to 4.1.3
22. Dr Zenas Yiu Present for all items

NICE staff (key players) present

Linda Landells, Associate Director Present for all items

Kate Moore, Project Manager Present for all items

Lizzie Walker, Heath Technology Assessment Adviser Items 1.1 to 4.1.3

Dilan Savani, Heath Technology Assessment Analyst Items 1.1 to 4.1.3

Mary Hughes, Heath Technology Assessment Adviser Items 5.1.1 to 5.2.2

Anita Sangha, Heath Technology Assessment Analyst Items 5.1.1 to 5.2.2

External assessment group representatives present

Robert Wolf, KSR - EAG representative Items 1.1 to 4.1.3

Willem Witlox, KSR - EAG representative Items 1.1 to 4.1.3

Caroline Farmer, PenTAG - EAG representative Items 5.1.1 to 5.1.3

Ashley Bullement, PenTAG - EAG representative Items 5.1.1 to 5.1.3

Clinical & Patient experts present

Lisa Suchet, Patient Expert, nominated by Tuberous Sclerosis Association

 Items 1.1 to 4.1.3

Pooja Takhar, Patient expert, nominated by Vitiligo Support UK

 Items 1.1 to 4.1.3

Professor Helen Cross, Director of the UCL Great Ormond Street Institute of Child Health – clinical expert, nominated by UCB Pharma Items 1.1 to 4.1.3

Victoria Tsang, Highly Specialist Paediatric Pharmacist – Neuroscience – clinical expert nominated by Neonatal & Paediatric Pharmacists Group (NPPG)

 Items 1.1 to 4.1.3

Dr Rhys Thomas, Clinical Senior Lecturer, Honorary Consultant in Epilepsy – clinical expert nominated by UCB Pharma Items 1.1 to 4.1.3

Dr Jonathan Bachelor, Consultant Dermatologist; Clinical Lead for Dermatology (PRUH and South Sites) – clinical expert, nominated by Vitiligo Support UK

 Items 5.1.1 to 5.1.3

Dr Viktoria Eleftheriadou, Consultant Dermatologist; Associate Professor – clinical expert, nominated by British Association of Dermatologists (BAD)

 Items 5.1.1 to 5.1.3

Emma Rush, CEO of Vitiligo Support UK – patient expert, nominated by Tuberous Sclerosis Association Items 5.1.1 to 5.1.3

Pawan Korpal, Patient expert, nominated by Vitiligo Support UK

 Items 5.1.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Megan John, welcomed members of the committee and other attendees present to the meeting.
	2. The Chair noted apologies from Elliot Dash and Giles Monnickendam.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 14 December 2023

### Appraisal of Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]

* 1. Part 1 – Open session
		1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from UCB Pharma
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10653).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Raju Reddy, Paul Caulfield, and Will Sullivan.
	2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10653>

### Appraisal of Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

* 1. Part 1 – Open session
		1. The Chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Incyte Corporation
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10893).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Carole Pitkeathley, Dr Ben Searle, and Dr Matthew Bradley.
	2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10893>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 8 February 2024 and will start promptly at 9:00am.